You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK)附屬與武漢社泰醫療訂立諮詢協議
格隆匯 12-20 18:49

格隆匯12月20日丨遠大醫藥(00512.HK)公吿,於2021年12月20日,遠大醫藥(中國)(一間公司持有99.84%的附屬公司)與武漢社泰醫療訂立了諮詢協議,內容為有關遠大醫藥(中國)向武漢社泰醫療提供若干關於在中國引進Sirtex的釔90Y樹脂微球選擇性內放射性治療肝癌技術的諮詢服務。

近年於中國銷售和應用Sirtex的主要產品SIR-Spheres釔90樹脂微球的上市申請已於2020年11月25日獲中國國家藥品監督管理局(藥監局)受理,而SIR-Spheres釔90樹脂微球治療方法已分別進入2019年版的中國原發性肝癌診療規範和二零一八年版中國結直腸癌肝轉移診斷和綜合治療指南,臨牀需求明確。因此,集團預見將Sirtex的SIR-Spheres釔90樹脂微球引進中國會有具大潛力。遠大醫藥(中國)於中國進行了製造和銷售醫藥產品多年,對中國醫藥和臨牀市場有深厚的經驗和知識。

董事(包括獨立非執行董事)認為,訂立諮詢協議可讓遠大醫藥(中國)運用其於中國醫藥行業的經驗及網絡,幫助Sirtex及武漢社泰醫療進一步引入SIRSpheres釔90樹脂微球及於中國上市,對集團(作為Sirtex HoldCo的主要股東)有益。集團亦會因向武漢社泰醫療提供諮詢服務而收取費用。集團於諮詢協議中所收取的費用為根據集團於進行諮詢協議下的交易時預計的成本、市場慣例以及市場情況等因素釐定的。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account